Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

HIV dynamics linked to memory CD4+ T cell homeostasis.

Murray JM, Zaunders J, Emery S, Cooper DA, Hey-Nguyen WJ, Koelsch KK, Kelleher AD.

PLoS One. 2017 Oct 19;12(10):e0186101. doi: 10.1371/journal.pone.0186101. eCollection 2017.

2.

Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.

Wen J, Yan M, Liu Y, Li J, Xie Y, Lu Y, Kamata M, Chen IS.

PLoS One. 2016 Apr 6;11(4):e0151572. doi: 10.1371/journal.pone.0151572. eCollection 2016.

3.

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, Delebecque F, Cornetta K, Rothe M, Baum C, Nicolson T, Koldej R, Zhang J, Keech N, Camba Colón J, Breton L, Bartlett J, An DS, Chen IS, Burke B, Symonds GP.

Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. doi: 10.1038/mtm.2013.11. eCollection 2014.

4.

Reduced evolutionary rates in HIV-1 reveal extensive latency periods among replicating lineages.

Immonen TT, Leitner T.

Retrovirology. 2014 Oct 16;11:81. doi: 10.1186/s12977-014-0081-0.

5.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

6.

Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies.

Reece JC, Martyushev A, Petravic J, Grimm A, Gooneratne S, Amaresena T, De Rose R, Loh L, Davenport MP, Kent SJ.

PLoS One. 2014 Apr 7;9(4):e93330. doi: 10.1371/journal.pone.0093330. eCollection 2014.

7.

Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Donahue DA, Bastarache SM, Sloan RD, Wainberg MA.

J Virol. 2013 Sep;87(17):9620-32. doi: 10.1128/JVI.01165-13. Epub 2013 Jun 26.

8.

Immunology of pediatric HIV infection.

Tobin NH, Aldrovandi GM.

Immunol Rev. 2013 Jul;254(1):143-69. doi: 10.1111/imr.12074. Review.

9.

Recent developments in human immunodeficiency virus-1 latency research.

Chan CN, Dietrich I, Hosie MJ, Willett BJ.

J Gen Virol. 2013 May;94(Pt 5):917-32. doi: 10.1099/vir.0.049296-0. Epub 2013 Jan 30. Review.

10.

HIV pathogenesis: dynamics and genetics of viral populations and infected cells.

Coffin J, Swanstrom R.

Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a012526. doi: 10.1101/cshperspect.a012526.

11.

Redefining the viral reservoirs that prevent HIV-1 eradication.

Eisele E, Siliciano RF.

Immunity. 2012 Sep 21;37(3):377-88. doi: 10.1016/j.immuni.2012.08.010. Review.

12.

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.

DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA.

Nat Chem. 2012 Sep;4(9):705-10. doi: 10.1038/nchem.1395. Epub 2012 Jul 15.

13.

Mechanisms of HIV Transcriptional Regulation and Their Contribution to Latency.

Schiralli Lester GM, Henderson AJ.

Mol Biol Int. 2012;2012:614120. doi: 10.1155/2012/614120. Epub 2012 Jun 3.

14.

Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication.

Tyagi M, Bukrinsky M.

Mol Med. 2012 Sep 25;18:1096-108. doi: 10.2119/molmed.2012.00194. Review.

15.

Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.

Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG.

AIDS. 2012 Jul 31;26(12):1483-90. doi: 10.1097/QAD.0b013e3283553638.

16.

An "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cells.

Reece J, Petravic J, Balamurali M, Loh L, Gooneratne S, De Rose R, Kent SJ, Davenport MP.

PLoS Pathog. 2012;8(4):e1002615. doi: 10.1371/journal.ppat.1002615. Epub 2012 Apr 5.

17.

HIV latency.

Siliciano RF, Greene WC.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. doi: 10.1101/cshperspect.a007096. Review.

18.

Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Rong L, Perelson AS.

PLoS Comput Biol. 2009 Oct;5(10):e1000533. doi: 10.1371/journal.pcbi.1000533. Epub 2009 Oct 16.

19.

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP.

Nat Med. 2009 Aug;15(8):893-900. doi: 10.1038/nm.1972. Epub 2009 Jun 21.

20.

Modeling HIV persistence, the latent reservoir, and viral blips.

Rong L, Perelson AS.

J Theor Biol. 2009 Sep 21;260(2):308-31. doi: 10.1016/j.jtbi.2009.06.011. Epub 2009 Jun 17. Review.

Supplemental Content

Support Center